Hydralyte: Q3 FY24 Quarterly Report and Appendix 4C: First Positive Operating Cash Flow Quarter Underpinned by Strong Financial and Operational Performance

Hydralyte: Completion of Divesture of Non-US Assets

Hydralyte: The Hydration Pharmaceuticals Company Limited Reports Earnings Results for the Half Year Ended June 30, 2024

Hydralyte: H1 FY24 Half Year Report and Appendix 4D: 29% reduction in Net Cash Used in Operating Activities alongside stable revenue

Hydralyte: Five By Five Bags Care Pharma's Hydralyte In Competitive Pitch

Hydralyte: Q1 FY24 Quarterly Report and Appendix 4C: 43% Reduction in YoY Net Operating Cash Use to Record Low

Hydralyte: Waiver of ASX Listing Rule 10.1 Granted

Hydralyte: Execution of Variation to Facility Agreement with PURE Asset Management, Company to Seek a Sale Transaction

Hydralyte: Appendix 4E - Preliminary Final Report

Hydralyte: The Hydration Pharmaceuticals Company Limited Reports Earnings Results for the Full Year Ended December 31, 2023